Pharmacology/Pharmaceutical Industry
Cohort study: no association was found between statin therapy and cognitive decline or incident dementia in older adults.
23 Jun, 2021 | 10:14h | UTCCommentaries: Statin Therapy Not Associated With Cognitive Decline, Dementia in Older Adults, Study Says – American College of Cardiology AND Effect of Statins on Cognitive Decline and Dementia in Older Adults – American College of Cardiology
Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
22 Jun, 2021 | 10:08h | UTCIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Related: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance AND M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials AND FDA: Why you should not use Ivermectin to treat or prevent COVID-19 AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 AND NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” AND Video (5min): Ivermectin for COVID-19 | A Doctor Explains
M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19.
21 Jun, 2021 | 08:45h | UTC
Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.
21 Jun, 2021 | 08:48h | UTC
Audio Interview: potential treatments for children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19.
18 Jun, 2021 | 08:33h | UTCAudio Interview: Covid-19 in Children – New England Journal of Medicine
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.
18 Jun, 2021 | 08:35h | UTCEditorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.
17 Jun, 2021 | 09:55h | UTCOriginal study (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Commentaries: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science AND Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP AND Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT AND Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Commentary on Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
M-A: Acute treatments for episodic migraine in adults.
18 Jun, 2021 | 08:18h | UTCAcute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis – JAMA (free for a limited period)
Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (free for a limited period)
Commentary on Twitter (thread – click for more)
Science marches breathlessly forward – or, at least tries to expand its indication.
Anti–calcitonin gene-related peptide antibody infusion, again, vs. placebo.
— Ryan Radecki, MD MS (@emlitofnote) June 17, 2021
RCT: Tofacitinib reduced the risk of death or respiratory failure in patients hospitalized with Covid-19 pneumonia.
17 Jun, 2021 | 09:58h | UTCTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Commentary on Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:43h | UTCCommentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
[Press release – not published yet] CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy.
17 Jun, 2021 | 09:49h | UTCCureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters
Press release: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
Commentary on Twitter (thread – click for more)
https://twitter.com/hildabast/status/1405276204526039041
Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:45h | UTCMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.
17 Jun, 2021 | 09:41h | UTCRelated: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Systematic review: Safety and effectiveness of metformin in patients with reduced renal function – safe and beneficial at a eGFR of 45 mL/min/1.73m2 or higher; possibly harmful at an eGFR of less than 30 mL/min/1.73m2.
17 Jun, 2021 | 09:37h | UTC
Commentary on Twitter
Safety of metformin for T2 diabetes in people with reduced kidney function
Associated with ⬇️ mortality and no ⬆️ risk of acidosis at an eGFR of > 45
Associated with fewer benefits & possible ⬆️ in the risk of acidosis at an eGFR <30 https://t.co/uOyarn11hM@goKDIGO pic.twitter.com/Ca05gc7FHi
— Prof Kamlesh Khunti (@kamleshkhunti) June 16, 2021
France recommends single dose of vaccine if previous Covid infection detected.
16 Jun, 2021 | 08:24h | UTCFrance recommends single dose of vaccine if previous Covid infection detected – Rfi
Related: [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
[Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant.
15 Jun, 2021 | 09:09h | UTCNews Release: Vaccines highly effective against hospitalisation from Delta variant – Public Health England
Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
Commentary on Twitter
NEWS — Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
— UK Health Security Agency (@UKHSA) June 14, 2021
(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.
15 Jun, 2021 | 09:12h | UTCCommentaries: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases AND Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT AND Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science AND Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP AND What the Novavax vaccine means for the global fight against Covid-19 – Vox
Commentary on Twitter (thread – click for more)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
M-A: Ibuprofen and other NSAIDs superior to codeine for managing outpatient postoperative pain.
15 Jun, 2021 | 08:55h | UTCOriginal Article: Managing postoperative pain in adult outpatients: a systematic review and meta-analysis comparing codeine with NSAIDs – Canadian Medical Association Journal
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom – “no evidence of a difference between the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) vaccines”.
14 Jun, 2021 | 08:52h | UTCImpact of vaccination on new SARS-CoV-2 infections in the United Kingdom – Nature Medicine
Commentaries on Twitter
The ChAdOx1 nCoV-19 and BNT162b2 #COVID19 #vaccines reduce incidence of new #SARSCoV2 infections by up to 65% with a single dose and up to 80% after two doses in the United Kingdom @kb_pouwels @ONS @Oxford_NDPH @UniofOxford https://t.co/K1f68MMYyO
— Nature Medicine (@NatureMedicine) June 9, 2021
First-dose vaccination with the Oxford–AstraZeneca or Pfizer–BioNTech vaccine against SARS-CoV-2 reduced the incidence of new infections in the UK by 61% and 66%, respectively, according to a study in @NatureMedicine. https://t.co/2TUFE1DeII pic.twitter.com/KuMtc1cD7l
— Nature Portfolio (@NaturePortfolio) June 9, 2021
Lab study shows sera from persons fully vaccinated with the Pfizer–BioNTech vaccine can effectively neutralize B.1.617 (Delta) and other SARS-CoV-2 variants.
14 Jun, 2021 | 08:53h | UTCBNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants – Nature
Commentary on Twitter
An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 and B.1.525. https://t.co/7lXCVe7sPY
— Carlos del Rio (@CarlosdelRio7) June 12, 2021
RCT: No difference in 30-day mortality with discontinuation vs. continuation of renin-angiotensin-system inhibitors in patients with COVID-19, but secondary and explorative analysis showed discontinuation of RAS-inhibition may lead to a faster and better recovery.
14 Jun, 2021 | 08:47h | UTCEditorial: RAS inhibition and COVID-19: more questions than answers?
Related randomized trials showing no benefit from discontinuation: Randomized trial: No benefit from discontinuing ACE Inhibitors and ARBs in patients admitted with COVID-19 AND Randomized trial: Renin–angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19
Perspective | Does vaccinating adults stop kids from spreading COVID too?
11 Jun, 2021 | 08:32h | UTCDoes vaccinating adults stop kids from spreading COVID too? – Nature
High COVID vaccine uptake may protect the unvaccinated.
11 Jun, 2021 | 08:34h | UTCHigh COVID vaccine uptake may protect the unvaccinated – CIDRAP
Original Study: Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals – Nature Medicine
Commentaries on Twitter
Just published @NatureMedicine
Evidence that "vaccination not only protects individuals who have been vaccinated but also provides cross-protection to unvaccinated individuals in the community" as seen in kids benefiting from high % of adults vaxxedhttps://t.co/IPQo6WTFZX pic.twitter.com/jtfD93onnn— Eric Topol (@EricTopol) June 10, 2021
https://twitter.com/niklasf/status/1402950991268433923
US donation of 500 million Pfizer vaccines could help ‘turn tide’ as Africa runs out of doses, says WHO.
11 Jun, 2021 | 08:31h | UTC
CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare.
11 Jun, 2021 | 08:28h | UTCSee also: CDC plans “emergency meeting” on rare heart inflammation following COVID-19 vaccines – CBC News
Related: Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men.